Very recently, Pietrantonio et al. [17] analyzed tumor biopsies and ctDNA of 22 RAS-BRAF-wild-type, HER2/MET-negative mCRC patients, which benefited from anti-EGFR treatment and then developed resistance. This evidence concerns the gene EGFR and neoplasm.